How to Qualify for Mounjaro: What the Criteria Actually Mean for You

You've looked at your BMI and you're wondering where you stand

Most people arriving at this question already have a number in mind. They've weighed themselves, done a quick calculation and want to know whether it's enough. If you want a full breakdown before reading on, the dedicated page on what BMI qualifies for Mounjaro walks through every threshold in detail. The straightforward answer is: BMI of 30 or above clears the first bar for Mounjaro's UK licence. If your BMI sits between 27 and 29.9, you can still qualify, provided at least one weight-related health condition is part of your picture. That's the threshold set out in the medicine's UK licence, and it's the starting point our prescribers work from.

What often surprises people is that the BMI number is genuinely just the start. A prescriber reads your health history, current medications, any relevant conditions, and whether there are reasons Mounjaro might not be appropriate for you. Certain conditions (a personal or close family history of medullary thyroid carcinoma, or a syndrome called MEN2, for example) would prompt a more cautious discussion. Previous pancreatitis falls into the same category. The consultation exists precisely to surface those details, not to create obstacles.

One practical habit worth building now: pull up the BMI thresholds for Mounjaro and check where your current figure sits before your consultation. It takes under a minute and means you arrive knowing your baseline. You can use the NHS BMI calculator linked above to get your number quickly.

For South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, UK guidance applies BMI thresholds that are 2.5 kg/m² lower throughout, so 27.5 rather than 30, and 24.5 rather than 27, as the relevant cut-offs. NICE's recommendations for tirzepatide (TA1026) confirm these adjusted thresholds explicitly.

What counts as a weight-related condition for Mounjaro qualification?

If your BMI is between 27 and 29.9, the condition you have alongside it matters. The licensed weight-related conditions that can bring you into qualifying territory include type 2 diabetes, high blood pressure (hypertension), dyslipidaemia (which covers raised LDL cholesterol, raised triglycerides or low HDL), obstructive sleep apnoea, and established cardiovascular disease such as a history of heart attack or stroke.

Prediabetes and osteoarthritis also feature in the clinical picture prescribers consider. These aren't always listed in the licence wording with the same prominence, but they are part of what a thorough clinical review takes into account. If you're unsure whether your condition qualifies, that uncertainty is exactly what a consultation is designed to resolve, our prescribers have that conversation regularly.

It's worth being clear about one thing: having a qualifying condition doesn't guarantee approval. The prescriber is weighing whether Mounjaro is appropriate for you specifically, not just ticking a box next to a diagnosis. That's what clinical review means in practice. You can explore whether you'd likely qualify in more detail if you want to think it through before booking.

NHS qualification vs. private qualification: two different conversations

The NHS criteria for Mounjaro are considerably narrower than the licensed criteria available through a private regulated pharmacy. Under the phased NHS rollout, the current threshold (from June 2025) requires a BMI of 40 or above alongside four or more specific weight-related conditions from a defined list. A second cohort opened in June 2026 for those with a BMI of 35 to 39.9 and four or more of those conditions. Even meeting those criteria doesn't guarantee access, availability varies by GP practice and area, and wrap-around dietary and lifestyle support is a condition of NHS treatment.

The licensed eligibility for private prescription is broader: BMI 30 or above, or 27 or above with a relevant condition, as described above. That gap is why many people who are clinically suitable under the medicine's licence aren't yet reached by NHS provision. A regulated online pharmacy operating within that licensed framework is a legitimate route, provided every prescription comes from a qualified prescriber following proper clinical assessment.

If cost is part of your thinking, the Mounjaro pricing page sets out what a private prescription typically involves. And if you want a broader view of the treatment landscape, the weight-loss treatment overview covers the options side by side. The NHS access picture, for what it is worth, is explained on the how to get Mounjaro page.

What the qualifying process looks like at nume

At nume, qualifying starts with a free online consultation, no GP referral needed, no waiting list. You answer questions about your health, weight history and current medications. A GPhC-registered Independent Prescriber reads your answers the same day. Not software. A real clinician, who can approve treatment, ask for more information, or decline where it isn't clinically appropriate.

If approved, identity is verified with photo ID, and weight is confirmed live on a short video call. That combination (clinical review plus identity and weight verification) is what separates a properly run service from the sellers operating without proper oversight. The MHRA has been explicit about the risks of obtaining these medicines from unverified sources: fake pens have caused serious harm, and the enforcement operation in 2025 seized approximately 20 million doses of illegally traded weight-loss medicines worth around £45 million.

Once approved, treatment is dispatched the same day if you order before 12pm Monday to Friday, and delivered free the next working day by DPD in plain packaging. Everything (consultation, prescription, delivery and 7-day aftercare) is included in one price, with no subscription attached. You can read more about what you need to qualify for Mounjaro before you start, or find out more about how nume works. When you're ready, check your eligibility with our prescribers.